Roche Boosts CKD Diagnosis with New AI Tool
Roche has bolstered its chronic kidney disease (CKD) diagnostic capabilities with a new AI-based tool. The Kidney KlinRisk Algorithm, developed in collaboration with KlinRisk Inc, is now integrated into Roche's navify® Algorithm Suite panel for CKD risk stratification. It became available in Europe and the UK on October 6, 2025.
The Kidney KlinRisk Algorithm uses machine learning to predict CKD before symptoms appear. It's designed for early risk assessment in adults with CKD, diabetes, or hypertension. By detecting CKD early, appropriate treatment can be initiated to delay or prevent kidney function decline.
The new tool complements Roche's existing Kidney KFRE Algorithm, which focuses on managing later stages of CKD. The Kidney KlinRisk Algorithm combines multiple input factors from routine blood and urine tests, aligning with clinical guidelines. This is significant as there's currently no single biomarker test to predict an elevated risk of CKD.
Roche's integration of the Kidney KlinRisk Algorithm into its navify® Algorithm Suite panel enhances CKD diagnosis and management. The tool's early risk assessment capabilities, combined with its alignment with clinical guidelines, can help improve patient outcomes and reduce the global burden of CKD.
